SCIENTIFIC INSIGHTS
Streamlined Preclinical Bioanalytical Strategies: Accelerate your time to IND
Cut timelines, not corners! In this 45-minute webinar learn approaches for optimizing preclinical bioanalysis for IND success
Discover how platform selection directly affects program speed with discussion around modality-specific assay development strategies that support faster, compliant bioanalytical workflows.
What will you learn?
As drug development timelines continue to compress, the need for streamlined bioanalytical strategies for pharmacokinetic (PK) and immunogenicity (ADA) assessment has never been greater. Optimal platform selection is highly dependent upon therapeutic modality – whether monoclonal antibody, oligonucleotide or antibody-drug conjugate (ADC) – and can significantly impact program timelines. This presentation describes accelerated, modality-specific approaches for PK and ADA assay development that reduce reliance on custom critical reagent generation, enabling more efficient bioanalytical workflows without compromising data quality or regulatory acceptability.
-
Tips for selecting the appropriate platform for PK assessment dependent upon drug modality
-
How to build PK and ADA assays without custom critical reagents
-
Strategies for accelerating sample testing to allow a quicker path to IND
Who may this interest?
-
Translational Biologists
-
PK Scientists
-
Toxicologists
-
Bioanalytical Scientists
-
LC-MS Analytical Chemists
Our experts will discuss lessons learned from their experiences and offer insight into the multiple stages of specific assays including critical reagents, regulatory standards, assay formats and timelines.
- Lynn Kamen, PhD: Executive Director, Scientific Office, BioAgilytix
- Jay Stringer, PhD: Associate Director, Operations, BioAgilytix
- Liz Nolff: Associate Director, Operations, BioAgilytix
.png?width=920&height=521&name=BZ%20Preclinical%20Webinar%202026%20Thumbnail%20(2).png "BZ Preclinical Webinar 2026 Thumbnail (2)")
Share this Resource
